產品詳情
簡單介紹：
重組人泛素偶聯酶E2 I，His蛋白與其它公司提供的重組蛋白不同，rHuUBE2I, His蛋白產品為采用CFS的無細胞麥胚蛋白合成系統(tǒng)表達出來的重組蛋白，可表達出對細胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時獨有的全自動蛋白純化技術則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人泛素偶聯酶E2 I，His蛋白（全長序列）產品可用于Western Blot驗證、抗體制備、蛋白檢測、ELISA等試驗中.
詳情介紹：
重組人泛素偶聯酶E2 I，His蛋白
| Synonyms | SUMO-protein Ligase, Ubiquitin Carrier Protein 9, Ubiquitin Carrier Protein I, Ubiquitin-conjugating Enzyme E2 I, Ubiquitin-protein Ligase I, p18 |
| Species | Human |
| Source | Escherichia coli. |
| Molecular Weight | 重組人泛素偶聯酶E2 I，His蛋白Approximately 19.5 kDa, a single non-glycosylated polypeptide chain containing 158 amino acids (a.a.) of human UBE2I/UBC9 and 8 a.a. vector sequence including 6 × His tag at N-terminus. |
| Quantity | 10μg/50μg/1000μg |
| AA Sequence | 重組人泛素偶聯酶E2 I，His蛋白MHHHHHHAMG TLNMSGIALS RLAQERKAWR KDHPFGFVAV PTKNPDGTMN LMNWECAIPG KKGTPWEGGL FKLRMLFKDD YPSSPPKCKF EPPLFHPNVY PSGTVCLSIL EEDKDWRPAI TIKQILLGIQ ELLNEPNIQD PAQAEAYTIY CQNRVEYEKR VRAQAKKFAP S |
| Concentration | See label. |
| Purity | > 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | Data is not available. |
| Physical Appearance | 重組人泛素偶聯酶E2 I，His蛋白Sterile Colorless liquid. |
| Formulation | A 0.2 μm filtered concentrated solution in 50 mM HEPES, pH 7.6, with 125 mM NaCl, 10 % Glycerol, 1 mM DTT. |
| Endotoxin | Less than 1 EU/μg of rHuUBC9, His as determined by LAL method. |
| Storage | Store at -20 °C. |
| 重組人泛素偶聯酶E2 I，His蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Yukita A, Hosoya A, Ito Y, et al. 2012. Bone, 50: 1092-9. 2. Duan X, Trent JO, Ye H. 2009. Anticancer Agents Med Chem, 9: 51-4. 3. Niedenthal R. 2009. Methods Mol Biol, 497: 63-79. 4. Shang Q, Xu C, Zhang J, et al. 2009. Proteins, 76: 266-9. |
| Background | SUMO-Conjugating Enzyme UBC9 belongs to the ubiquitin-conjugating enzyme family and is encoded by the UBE2I gene in humans. The ubiquitin-conjugating enzymes, also known as E2 enzymes and more rarely as ubiquitin-carrier enzymes, take part in the second step in the ubiquitination reaction. In this reaction, E1 activates the ubiquitin by covalently attaching the molecule to its active site cysteine residue. The activated ubiquitin is then transferred to an E2 cysteine and then the E2 molecule binds E3 via a structurally conserved binding region. The UBC9 accepts the ubiquitin-like proteins SUMO1-4 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2 or CBX4. Additionally, It takes parts in catalysis the formation of poly-SUMO chains, sumoylation of FOXL2 and KAT5, and the segregation of nuclear architecture and chromosome. |
